1F5 (ATCC® HB-9645)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Applications
The antibody is specific for CD20 (expressed on normal and neoplastic human B cells) and can induce proliferation of resting B cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against human CD20 B cell antigen (Bp35)
Cellular Products
immunoglobulin; monoclonal antibody; against human CD20 B cell antigen (Bp35)
Comments
The antibody is specific for CD20 (expressed on normal and neoplastic human B cells) and can induce proliferation of resting B cells.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Culture Conditions
Temperature: 37.0°C
Isotype IgG2a
Name of Depositor Bristol-Myers Co.
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
References

Senter PD, et al. Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells. US Patent 4,975,278 dated Dec 4 1990

Clark EA, et al. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA 82: 1766-1770, 1985. PubMed: 3872456

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Senter PD, et al. Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells. US Patent 4,975,278 dated Dec 4 1990

Clark EA, et al. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. USA 82: 1766-1770, 1985. PubMed: 3872456